Trading Radar 7/14: Genentech (DNA), Novellus (NVLS) Report; PPI, Retail Sales, Business Inventories Due
More News related to DNA
- Biogen Idec (BIIB) Announces Decision By Arbitration Panel in Issues with Genentech (DNA)
- Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
- FDA ODA Committee Recommends Accelerated Approval of Genentech's (DNA) Avastin for Brain Cancer
- Genentech (DNA) said FDA committee unamiously recommends accelerated approval of Avastin in brain cancer
- Moody's Downgraded Rating On Roche Following Genentech Buyout
More News related to NVLS
- Novellus Announces Availability and Timing of Second Quarter 2009 Earnings and Analyst and Press Event at Semicon West
- Novellus Rated a Top Semiconductor Equipment Supplier by VLSI Research
- Goldman Sachs Added Novellus Systems (NVLS) to their Conviction Sell List
- Novellus' Peter Wolters Division Develops 22nm Double-Sided Silicon Wafer Polish Process
- Novellus' Ultra Low Dielectric Constant Materials Enable 32nm Device Integration
StreetInsider.com Trading Radar:
Before Market Opens:
Economics:
8:30 AM ET
- Core PPI for June - Street expects 0.3%, compared to 0.2% in May
- PPI for June - Street expects 1.3%, compared to 1.4% in May
- Retail Sales for June - Street expects 0.3%
Economics:
10:30 AM ET
- Business Inventories for May - Street expects 0.5%, compared to 1.2% in April
Novellus Systems (Nasdaq: NVLS) - consensus EPS $0.24, revs $251.54M
After Market Closes:
Earnings:
Genentech (NYSE: DNA) - consensus EPS $0.86, revs $3.23B
Subscribe to EasyStockAlerts and get real-time e-mail alerts when news hits your stocks!
Related Categories
Special ReportsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
